Washington Examiner
· collected 2026-09-17 · by Rep. Brad Wenstrup
Voters are increasingly concerned about the affordability of prescription drugs, with healthcare costs ranking as their top economic worry. Republicans argue that they have effective solutions like transparency in pharmacy benefit manager practices and free-market competition rather than government price-setting. The article highlights Trump’s Most-Favored-Nation negotiations and the proposed USTRx Act to ensure foreign governments pay a fair share for pharmaceutical innovation, countering the current situation where American patients bear an excessive financial burden while other countries leverage steep discounts from American drugmakers.
Written locally by qwen2.5:14b on 2026-09-17,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Heading into November, voters rank healthcare costs as their single biggest economic worry.
asserted
voters → head → worry
For the first time since Kaiser Family Foundation began tracking the question in 2018, a majority now say they’re specifically anxious about affording their prescriptions.
asserted
they → track → prescriptions
And right now, voters trust Democrats more than Republicans to do something about it, by roughly 12 points, and by a similar margin on drug affordability specifically.
asserted
voters → trust → affordability
Republicans can close that gap.
asserted
Republicans → close → gap
We have the ideas that actually work, such as transparency and free-market competition rather than Washington price-setting, and trade leverage instead of surrendering to foreign governments that have spent decades exploiting American drug innovation.
asserted
that → have → innovation
I’ve made that case from a medical practice in Ohio and from battlefields abroad, and I’ve watched it hold up under pressure: Lowering costs for American families requires exposing who’s actually driving costs up, at home and abroad.
asserted
who → make → home
For example, the Better Deals and Lower Prices Act, signed into law by President Donald Trump, forced pharmacy benefit managers, the middlemen who have long operated in the dark, to give employers and patients real visibility into the rebates and fees that have quietly driven up the price of prescriptions.
asserted
that → sign → prescriptions
The bipartisan No Surprises Act, on the other hand, mandates payment disputes between insurers and doctors be settled by a neutral arbiter weighing real market factors, not by Washington setting a fixed rate.
asserted
Washington → mandate → rate
Both efforts rest on the same principle: hold the system accountable and attack what’s actually driving up costs while maintaining America’s healthcare leadership.
asserted
what → rest → leadership
Now America is taking on another cost driver, one that reaches past our own borders.
asserted
that → take → borders
For years, American patients have shouldered a disproportionate share of the cost of the innovation the entire developed world relies on.
asserted
world → shoulder → innovation
Wealthy governments in Europe and elsewhere impose price controls on their own markets and squeeze steep discounts out of American drugmakers, knowing the U.S. market will make up the difference by paying more.
asserted
market → impose → more
Trump’s most-favored-nation negotiations are chipping away at that imbalance by lowering what Americans pay.
asserted
Americans → favor → what
But that’s only one side of the ledger.
asserted
that → ’ → ledger
If foreign governments respond by driving their own prices down even further, the money that funds tomorrow’s cures doesn’t shift to America; it just disappears.
asserted
it → respond → America
Americans should pay less while foreign governments pay their fair share, too.
asserted
governments → pay → share
The USTRx Act can make a difference.
asserted
Act → make → difference
The bill would create a chief pharmaceutical trade negotiator inside the Office of the U.S. Trade Representative to identify foreign price controls and market barriers that disadvantage American patients and innovation.
asserted
that → create → patients
Our negotiators would have real leverage to make foreign governments pay their share.
asserted
governments → have → share
Germany is the case in point happening right now.
asserted
Germany → happen → point
Berlin is pushing a new rebate scheme that would squeeze American drugmakers further.
asserted
that → push → drugmakers
That’s precisely the kind of quiet cost-shifting the USTRx Act is built to confront before foreign schemes get locked in.
asserted
schemes → ’ → shifting
Republicans leading in this effort can increase public trust.
asserted
Republicans → lead → trust
A McLaughlin & Associates poll found 72% of voters agree it’s time to make other countries pay their fair share for prescription drugs.
asserted
countries → find → drugs
Voters want Congress to act.
asserted
Congress → want → ?
Trust grows not with better talking points but with results, such as exposing pharmacy middlemen, holding insurers accountable, and getting foreign governments to pay their share.
asserted
governments → grow → share
I’ve left elected office, but my fight for patients doesn’t stay behind.
asserted
fight → leave → patients
The world benefits from American medicine.
asserted
world → benefit → medicine
It’s time the world paid for it.
asserted
world → ’ → it
The Aporia
